Treatment Efficacy Score—continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between randomized trial arms in breast cancer trials von Marczyk, M., Mrukwa, A., Yau, C., Wolf, D., Chen, Y.-Y., Balassanian, R., Nanda, R., Parker, B.A., Krings, G., Sattar, H., Zeck, J.C., Albain, K.S., Boughey, J.C., Liu, M.C., Elias, A.D., Clark, A.S., Venters, S.J., Shad, S., Basu, A., Asare, S.M., Buxton, M., Asare, A.L., Rugo, H.S., Perlmutter, J., DeMichele, A.M., Yee, D., Berry, D.A., Veer, L. van’t, Symmans, W.F., Esserman, L., Pusztai, L.

Volltext

OA11.04 Volrustomig + platinum doublet chemotherapy (CTx) in first-line non-small cell lung cancer (NSCLC): Phase 1b trial update von Spigel, D.R., Ahn, M.-J., Majem, M., Medina Rodríguez, L., Lee, K.H., Carcereny, E., Hernández, A.A., Insa, A., Cho, E.K., Besse, B., Rha, S.Y., Weiss, J., D'Arcangelo, M., Im, S.-A., Kim, S.-W., Carneiro, B.A., Gadgeel, S.M., Mitchell, P., Asare, J.M., Gainer, S.D., Achour, I., Subramaniam, D.S., Felip, E.

Volltext